Información de Altimmune Inc, dividendo de Altimmune Inc, actividades de los accionistas y más

Más Datos de Altimmune Inc Compañía

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Información de Altimmune Inc



Símbolo de cotizaciónALT

Nombre de la empresaAltimmune Inc

Fecha de salida a bolsaOct 06, 2005

Director ejecutivoDr. Vipin K. Garg, Ph.D.

Número de empleados59

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 06

Dirección910 Clopper Road

CiudadGAITHERSBURG

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal20878-1361

Teléfono12406541450

Sitio Webhttps://altimmune.com/

Símbolo de cotizaciónALT

Fecha de salida a bolsaOct 06, 2005

Director ejecutivoDr. Vipin K. Garg, Ph.D.

Ejecutivos de Altimmune Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Ms. Linda M. Richardson

Chief Commercial Officer

--

Mr. Philip L. Hodges

Independent Director

--

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board

--

Dr. M. Scot Roberts, Ph.D.

Chief Scientific Officer

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: mar., 4 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Otro

81.23%

Accionistas

Proporción

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Otro

81.23%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

20.68%

Investment Advisor/Hedge Fund

9.49%

Hedge Fund

7.78%

Research Firm

3.16%

Individual Investor

0.73%

Bank and Trust

0.38%

Pension Fund

0.05%

Insurance Company

0.03%

Otro

57.70%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

405

38.06M

36.57%

-11.64M

2025Q2

413

40.03M

49.36%

-12.37M

2025Q1

433

39.51M

48.72%

-15.43M

2024Q4

439

41.91M

54.50%

-15.25M

2024Q3

440

40.83M

57.43%

-21.59M

2024Q2

436

43.67M

61.47%

-20.29M

2024Q1

418

45.76M

64.68%

-11.45M

2023Q4

387

34.44M

49.06%

-14.90M

2023Q3

368

31.34M

59.36%

-25.59M

2023Q2

362

36.16M

68.78%

-25.80M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

5.17M

5.85%

+772.36K

+17.57%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.75M

6.52%

+223.90K

+4.05%

Jun 30, 2025

State Street Investment Management (US)

2.75M

3.12%

-637.93K

-18.81%

Jun 30, 2025

Tang Capital Management, LLC

2.75M

3.12%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

1.93M

2.19%

+229.00K

+13.42%

Jun 30, 2025

Susquehanna International Group, LLP

1.62M

1.84%

+543.68K

+50.53%

Jun 30, 2025

Knoll Capital Management, LLC

1.12M

1.27%

--

Jun 30, 2025

Caption Management, LLC

980.78K

1.11%

+941.92K

+2423.62%

Jun 30, 2025

BofA Global Research (US)

716.02K

0.81%

+435.47K

+155.22%

Jun 30, 2025

UBS Financial Services, Inc.

633.56K

0.72%

-94.60K

-12.99%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Invesco NASDAQ Future Gen 200 ETF

0.48%

Virtus LifeSci Biotech Clinical Trials ETF

0.38%

SPDR S&P Biotech ETF

0.15%

Direxion Daily S&P Biotech Bull 3X Shares

0.08%

Fidelity Enhanced Small Cap ETF

0.06%

iShares Micro-Cap ETF

0.06%

iShares Biotechnology ETF

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Russell 2000 Growth ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

Proporción0.48%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.38%

SPDR S&P Biotech ETF

Proporción0.15%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.08%

Fidelity Enhanced Small Cap ETF

Proporción0.06%

iShares Micro-Cap ETF

Proporción0.06%

iShares Biotechnology ETF

Proporción0.03%

Invesco Nasdaq Biotechnology ETF

Proporción0.03%

ProShares Ultra Nasdaq Biotechnology

Proporción0.03%

iShares Russell 2000 Growth ETF

Proporción0.02%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos